mdm2与p53在骨骼肌恶性肿瘤中的改变及其临床意义

目的：探讨ｍｄｍ２与Ｐ５３基因在骨骼肌恶性肿瘤中的改变及其临床意义。方法采用ＲＮＡ打点杂交技术分析２０例骨骼肌恶性肿瘤中的ｍｄｍ２与Ｐ５３基因的表达水平，采用ＰＣＲ－ＳＳＣＰ技术分析Ｐ５３基因的突变情况，结合随访结果，分析其临床意义，结果①ＲＮＡ打点杂交结果：ｍｄｍ２基因在１０例恶性肿瘤标本中呈高表达，在８例肿瘤标本与２０例瘤旁标本中呈低表达，ｍｄｍ２的表达在骨骼肌恶性肿瘤中显示高于瘤旁组织（Ｐ

Alteration of mdm2 and p53 in musculoskeletal tumors and its clinical significance

AIM To explore the alteration of mdm 2 and p53 in musculoskeletal tumors and its clinical significance. METHODS By using RNA dotblot and PCR SSCP, we analyzed the alteration of mdm 2 and p53 in 20 specimens of musculoskeletal tumors and paired peritumorous tissues and made a follow up study of the patients for 3 years after the operation for the clinical significance of the change. RESULTS By using RNA dotblot, it was found that mdm 2 was overexpressed in 10 specimens of musculoskeletal tumors, lowexpressed in 8 specimens of musculoskeletal tumors and 18 of peritumorous tissues, indicating that there was a significant difference between the mdm 2 expressions in bone tumors and peritumorous tissues ( P <0.01). p53 was overexpressed in 12 specimens of musculoskeletal tumors and lowexpressed in 20 specimens of peritumorous tissues, indicating that there was a significant difference between p53 expressions in bone tumors and peritumorous tissues ( P <0 01). PCR SSCP analysis didn't show any mdm 2 mutation in the specimens, but in 9 specimens of bone tumors p53 mutation was discovered. Results of the 3 year follow up study: 3 of the 9 patients with mutation of p53 died 6 months after the operation and 4 died 12 months after the operation and 21.5 years after the operation. 6 of the 11 patients without mutation of p53 died at 2 years after the operation and 1 died 3 years later, and 4 are still alive. CONCLUSION mdm 2 gene takes part in the progress of musculoskeletal tumors by overexpression and p53 gene by mutation and overexpression. It is probably helpful for prognosis to screen mdm 2 overexpression and p53 alteration in musculoskeletal tumors.